We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current ADXS market cap is 2.69M. The company's latest EPS is USD 0.0000 and P/E is N/A.
| Year End December 30 2022 | 2019 | 2020 | 2021 | 2022 | 2022 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 20.88M | 253k | 3.24M | 250k | 0 |
| Operating Income | -17.97M | -26.45M | -18.79M | -19.31M | 0 |
| Net Income | -16.61M | -26.47M | -17.86M | -15.38M | 0 |
| Year End December 30 2022 | 2019 | 2020 | 2021 | 2022 | 2022 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 45.26M | 38.53M | 46.78M | 25.93M | 7.77M |
| Total Liabilities | 5.73M | 8.35M | 7.89M | 2.3M | 8.87M |
| Total Equity | 39.53M | 30.18M | 38.89M | 23.63M | -1.1M |
| Year End December 30 2022 | 2019 | 2020 | 2021 | 2022 | 2022 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -36.13M | -21.94M | -15.44M | -15.28M | N/A |
| Investing | -1.2M | -748k | -11k | -166k | N/A |
| Financing | 24.57M | 15.5M | 31.89M | -956k | N/A |
| Market Cap | 2.69M |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0.48 |
| Price to Book Ratio | -1.06 |
| Dividend Yield | - |
| Shares Outstanding | 4.84M |
| Average Volume (1 week) | 876 |
| Average Volume (1 Month) | 3.12k |
| 52 Week Change | -50.45% |
| 52 Week High | 1.95 |
| 52 Week Low | 0.50 |
| Spread (Intraday) | 0.11 (16.54%) |
| Company Name | Ayala Pharmaceuticals Inc (QX) |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.ayalapharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
